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DOI 10.1016/j.ccr.2011.09.011SUMMARYTherapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) is a major complication of cancer
treatment. We compared gene expression in CD34+ cells from patients who developed t-MDS/AML after
autologous hematopoietic cell transplantation (aHCT) for lymphoma with controls who did not develop
t-MDS/AML.We observed altered gene expression related tomitochondrial function,metabolism, and hema-
topoietic regulation in pre-aHCT samples from patients who subsequently developed t-MDS/AML. Progres-
sion to overt t-MDS/AMLwas associatedwith additional alterations in cell-cycle regulatory genes. An optimal
38-gene PBSC classifier accurately distinguished patients who did or did not develop t-MDS/AML in an inde-
pendent group of patients. We conclude that genetic programs associated with t-MDS/AML are perturbed
long before disease onset, and accurately identify patients at risk for this complication.INTRODUCTION
Therapy-related myelodysplasia or acute myeloid leukemia
(t-MDS/AML) is a lethal complication of cytotoxic cancer
therapy. Among patients undergoing autologous hematopoietic
cell transplantation (aHCT) for Hodgkin lymphoma (HL) or non-
Hodgkin lymphoma (NHL), t-MDS/AML is a leading cause of
nonrelapse mortality (Bhatia et al., 1996, 2005; Miller et al.,
1994; Pedersen-Bjergaard et al., 2000; Stone et al., 1994). Pre-
aHCT therapeutic exposures, transplant conditioning, autograft
collection, and hematopoietic regeneration contribute to devel-
opment of t-MDS/AML (Bhatia et al., 1996; Kalaycio et al.,
2006; Krishnan et al., 2000). The overwhelming majority of
patients develop t-MDS/AML within 6 years after aHCT.
However, the timing and sequence of acquisition of molecularSignificance
Therapy-related myelodysplasia or acute myeloid leukemia
However, the pathogenesis of t-MDS/AML is poorly understoo
in individual patients are not available. Using gene expression a
metabolism, and hematopoietic regulation in hematopoietic c
ment of cytogenetic and pathological abnormalities. A t-MDS
group of patients accurately distinguished patients who did o
indicate that perturbations in genetic programs associated w
can accurately identify patients at risk for developing this com
Canabnormalities leading to t-MDS/AML is unknown. t-MDS/AML
accounts for 15% of all AML and MDS cases and shares
morphologic and cytogenetic characteristics with primary MDS
and AML in the elderly. Study of t-MDS/AML offers a unique
opportunity to understand leukemogenesis because known gen-
otoxic exposures can be temporally and causally related to
genetic changes associated with subsequent development of
leukemia (Mason, 2003; Pedersen-Bjergaard, 2005).
To better understand the pathogenetic mechanisms under-
lying t-MDS/AML, we have constructed a prospective cohort
of patients undergoing aHCT for HL or NHL. Patients are fol-
lowed longitudinally with collection of peripheral blood stem cells
(PBSC) and bone marrow (BM) samples prior to a-HCT, and
serial BM samples until 5 years post-aHCT. This design allows
use of a nested case-control approach to compare gene(t-MDS/AML) is a lethal complication of cancer treatment.
d and methods to predict risk of t-MDS/AML development
nalysis we detected abnormalities inmitochondrial function,
ells early in t-MDS/AML pathogenesis, long before develop-
/AML gene expression signature applied to an independent
r did not subsequently develop t-MDS/AML. These results
ith t-MDS/AML are present long before disease onset, and
plication in the future.
cer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 591
Figure 1. Altered Gene Expression in PBSC CD34+ Cells from t-MDS/AML Cases Compared with Controls
(A) The study design is shown. Gene expression was compared between (1), pre-aHCT PBSC samples obtained from cases (n = 18) versus controls (n = 37); (2),
BM samples obtained from cases at time of t-MDS/AML (n = 12) versus BM samples obtained from controls at comparable time points post-aHCT (n = 21); and
(3), changes in gene expression over time from PBSC collection to development of t-MDS/AML in cases compared with gene expression changes over
a comparable time period in controls (D t-MDS/AML-PBSC).
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Genetic Alterations Preceding Leukemia Developmentexpression profiles in CD34+ hematopoietic stem and progenitor
cells (HSC) from ‘‘cases’’ that developed t-MDS/AML after aHCT
with ‘‘controls’’ who did not develop t-MDS/AML. In the current
report, PBSC procured pre-aHCT and BM samples obtained at
time of t-MDS/AML post-aHCT were studied. This approach
facilitated identification of gene expression changes pre-aHCT
in patients who subsequently developed t-MDS/AML after
aHCT. This approach also allowed a comparison of gene expres-
sion pre-aHCT with that seen at development of overt t-MDS/
AML. Finally, using an independent sample set (test set), we
investigated whether gene expression in pre-aHCT samples
could accurately identify patients at risk for development of
post-aHCT t-MDS/AML.
RESULTS
We compared gene expression in CD34+ cells from the training
set consisting of 18 cases that developed t-MDS/AML and
37 matched controls that did not develop t-MDS/AML after
aHCT for HL or NHL. One to three randomly selected controls
were individually matched to each case for primary diagnosis
[HL/NHL], age at aHCT (±10 years), and race/ethnicity (Cauca-
sians, African-Americans, Hispanics, other). The median time
to t-MDS/AML post-aHCT was 2.7 years (range, 0.5–5.2 years).
For each case, controls were selected that had been followed for
a length of time that exceeded the latency from aHCT to t-MDS
for the index case, to ensure that the probability of the controls
developing t-MDS subsequently was minimized. The length of
follow-up from aHCT for cases was 33.4 months (range: 5.9–
63.7 months) and for controls was 116 months (range: 75.8–
136 months). The clinical and demographic characteristics of
the cases and controls are shown in Table S1 available online.
Comparison of cases with controls revealed no significant
differences in primary diagnosis, sex, race/ethnicity, age at
primary diagnosis and aHCT, stem cell source and mobilization
regimens, number of PBSC collections, CD34+ cell dose, and
conditioning regimens. Detailed analysis of pre-aHCT thera-
peutic exposures (including cumulative doses), HCT-related
conditioning, and post-aHCT therapeutic exposure (in the event
of relapse) did not reveal any statistically significant difference
in the intensity or nature of therapeutic exposures between
case and controls (Table S1). The clinical and pathological char-
acteristics of the 18 patients with t-MDS/AML are shown in Table
S2. We studied PBSC samples from the 18 cases and 37
matched controls, and BM samples obtained at time of t-MDS/
AML fromasub-cohort of 12casesand21matchedcontrols (Fig-
ure 1A). This subset of 12 cases did not differ significantly in
clinical or demographic characteristics from the parent group.
Gene expression profiles in CD34+ cells from t-MDS/AML cases
andmatchedcontrolswerecomparedusingconditional logistical
model (CLM) (Figure 1A). The following comparisons weremade:
(1), pre-aHCT PBSC from cases versus controls; (2), BM from
cases at t-MDS/AML versus BM from controls at a comparable(B) Differences in gene expression in PBSC CD34+ cells from cases and controls
[>4 or < 0.25]).
(C) Expression of representative gene sets within individual PBSC CD34+ cells fr
the genes in each gene set and hierarchical clustering was performed for samples
expression resembling that of controls. See also Figure S1, Table S1, Table S2,
Cantime point post-aHCT; and (3), changes in gene expression
from pre-aHCT to development of t-MDS/AML in cases versus
controls over a comparable time period (D t-MDS/AML-PBSC).
The results of the training set were validated in an independent
group of 36 patients (test set) consisting of 16 cases that devel-
oped t-MDS/AML post-aHCT and 20 matched controls.
Gene Expression in PBSC CD34+ Cells Preceding Onset
of t-MDS/AML
This analysis was directed toward identifying genetic changes
in pre-aHCT samples. Unsupervised clustering of cases and
controls usingall genes (filtered to remove those thatwere not ex-
pressed or with minimal differences across the cohort) showed
that samples clustered into two major groups, with five cases
clustering with controls and 11 controls clustering with cases
(Figure S1A). PBSC from patients who developed t-MDS/AML
demonstrated significant differences in gene expression
compared to controls (Figure 1B). A total of 779 genes were up-
regulated and 2220 genes were downregulated in t-MDS/AML
cases compared to controls, based on the criteria of absolute
odds ratio (OR) > 4 and p value < 0.05. If using absolute OR > 4
and p value < 0.01, 44 genes were upregulated and 301 genes
were downregulated in t-MDS/AML cases compared to controls.
Gene set enrichment analysis (GSEA) was performed to
determine concordant differences between differentially ex-
pressed genes and curated gene sets (Subramanian et al.,
2005) (Table 1; Table S3). PBSC from patients who subsequently
developed t-MDS/AML (cases) showed significant downreg-
ulation of gene sets related to mitochondria and oxidative
phosphorylation (Figure S1B), citrate cycle, ribosomal proteins
(Figure S1B), aminoacyl-tRNA biosynthesis, amino acid metabo-
lism, cell cycle regulation, DNA repair, and hematopoietic
differentiation. G protein coupled receptors, cell communication
(Figure S1B), hematopoietic regulation, and cell adhesion related
genes were upregulated in PBSC from cases. There was re-
duced expression of genes with binding motifs for NRF2 and
GABP (regulators of mitochondrial enzymes) (Lenka et al.,
1998), and E2F1 (regulator of cell cycle) (Chen et al., 2009),
and increased expression of genes with binding motifs for
GFI1 and FOXA1 (regulators of hematopoiesis) (Tothova et al.,
2007) and OCT1 (regulator of DNA damage response) (Kang
et al., 2009) (Table S3). In agreement with GSEA results, Inge-
nuity pathway analysis (IPA) indicated that pathways related to
mitochondrial function, oxidative phosphorylation, protein ubiq-
uitination, aminoacyl-tRNA synthesis, cell cycle regulation,
citrate cycle, and amino acid metabolism, were significantly
altered in cases compared to controls (Table S3). Gene ontology
(GO) analysis also indicated significant reduction in mitochon-
drial function and oxidative phosphorylation, cell metabolism,
protein synthesis, and cell cycle regulation in cases; and enrich-
ment of genes related to GTPase activity and transcription
factors, tissue/organ development and cell communication
(Table S3). Thus, multiple analytical approaches consistentlyare shown for top 50 genes (with the smallest p values and 4-fold change in OR
om individual cases and controls is shown. The expression was averaged over
within the case and control groups. The box indicates the five cases with gene
and Table S4.
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Table 1. Gene Sets Enriched in PBSC CD34+ Cells from Patients Who Later Develop t-MDS/AML
Gene Set
Training Set Test Set
NES FDR q Value NES FDR q Value
Enriched in cases
G-Protein coupled receptors
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 2.83 <0.001 3.89 <0.001
GPCRDB_CLASS_A_RHODOPSIN_LIKE 2.60 <0.001 3.35 <0.001
GPCRS_CLASS_A_RHODOPSIN_LIKE 2.52 <0.001 2.83 <0.001
MONOAMINE_GPCRS 2.32 0.003 2.62 <0.001
PEPTIDE_GPCRS 2.21 0.005 2.86 <0.001
Hematopoietic regulation
HALMOS_CEBP_DN 2.33 0.003 1.73 0.079
HOX_GENES 1.89 0.036 1.06 0.738
HSA04340_HEDGEHOG_SIGNALING_PATHWAY 1.76 0.058 2.15 0.005
Cell adhesion/communication
HSA01430_CELL_COMMUNICATION 2.05 0.009 2.86 <0.001
CELL_ADHESION 1.63 0.108 1.82 0.061
Xenobiotic metabolism
GAMMA_HEXACHLOROCYCLOHEXANE_DEGRADATION 2.04 0.009 2.01 0.018
Enriched in controls (reduced in cases)
Mitochondria and oxidative phosphorylation
HUMAN_MITODB_6_2002 2.92 <0.001 3.93 <0.001
HSA00190_OXIDATIVE_PHOSPHORYLATION 2.88 <0.001 3.01 <0.001
ELECTRON_TRANSPORT_CHAIN 2.85 <0.001 3.17 <0.001
MITOCHONDRIA 2.84 <0.001 3.85 <0.001
MOOTHA_VOXPHOS 2.74 <0.001 3.08 <0.001
OXIDATIVE_PHOSPHORYLATION 2.58 <0.001 2.67 <0.001
Ribosomes
HSA03010_RIBOSOME 3.02 <0.001 4.06 <0.001
RIBOSOMAL_PROTEINS 3.01 <0.001 3.77 <0.001
tRNA biosynthesis
TRNA_SYNTHETASES 2.68 <0.001 2.71 <0.001
AMINOACYL_TRNA_BIOSYNTHESIS 2.41 <0.001 2.74 <0.001
HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS 2.27 <0.001 2.76 <0.001
Proteasomal pathway
PROTEASOMEPATHWAY 2.47 <0.001 3.14 <0.001
HSA03050_PROTEASOME 2.47 <0.001 2.69 <0.001
PROTEASOME_DEGRADATION 2.32 <0.001 2.52 <0.001
Cell cycle regulation
DNA_REPLICATION_REACTOME 2.37 <0.001 2.64 <0.001
P21_P53_MIDDLE_DN 2.26 <0.001 1.45 0.107
P21_P53_ANY_DN 2.16 6.79E-04 2.33 <0.001
SERUM_FIBROBLAST_CELLCYCLE 2.14 0.014456 1.74 0.029
CELL_CYCLE_KEGG 1.91 0.005942 1.97 0.008
Metabolism
KREBS_TCA_CYCLE 2.46 <0.001 2.46 <0.001
HSA00020_CITRATE_CYCLE 2.23 2.31E-04 2.55 <0.001
PENG_LEUCINE_DN 2.22 4.46E-04 3.65 <0.001
HSA00252_ALANINE_AND_ASPARTATE_METABOLISM 2.05 0.001727 1.00 0.535
PROPANOATE_METABOLISM 1.98 0.003869 2.82 <0.001
Hematopoietic stem cells
HSC_INTERMEDIATEPROGENITORS_ADULT 2.42 <0.001 3.15 <0.001
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Table 1. Continued
Gene Set
Training Set Test Set
NES FDR q Value NES FDR q Value
HSC_LATEPROGENITORS_ADULT 2.36 <0.001 3.73 <0.001
HSC_INTERMEDIATEPROGENITORS_SHARED 2.35 <0.001 3.19 <0.001
HSC_LATEPROGENITORS_FETAL 2.31 <0.001 3.61 <0.001
HSC_LATEPROGENITORS_SHARED 2.28 <0.001 3.87 <0.001
DNA repair
BRENTANI_REPAIR 2.23 <0.001 1.68 0.039
FDR, false discovery rate; NES, normalized enrichment scores. See also Table S3.
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chondrial function, oxidative phosphorylation, and cellular
response to oxidative and genotoxic stresses in PBSC samples
from patients who subsequently develop t-MDS/AML.
Expression of enriched genes from representative gene sets in
individual PBSC samples is shown in Figure 1C and Figure S1C.
Five of 18 PBSC samples from the cases demonstrated gene
expression resembling that of controls. These five cases (#11,
#62, #101, #125, and #168,) were the same as those identified
on hierarchical clustering analysis using all genes. For the five
patients that were misclassified, one patient (#11) had transient
myelodysplasia with del 7 that subsequently resolved, one
patient (#168) developed transient del(20q), two patients devel-
oped persistent del(20q) or del(13q) abnormalities with mild
dysplasia (#62 and #125), and one patient developed AML with
11q23 translocation (#101) (Gupta et al., 2007; Han and Theil,
2007). The remaining 13 cases showing clearly altered gene
expression in PBSC samples compared to controls, later pre-
sented with overt t-MDS/AML. Reanalysis of data after removing
the two transient cases and their controls showed enrichment
of gene sets in cases and controls that were highly similar
to those seen in the original analysis (Figure S1D). The major
categories of gene sets upregulated in cases (GPCRs, hemato-
poietic transcription factors [CEBP], cell communication, xeno-
biotic metabolism) and downregulated in cases (upregulated in
controls) (mitochondrial oxidative phosphorylation, ribosomes,
aminoacyl-tRNA synthetases, proteasomal degradation, citric
acid cycle, cell cycle, DNA repair and hematopoietic stem cells)
were maintained in the new analysis (Table S4).
Gene Expression at Time of t-MDS/AML
To evaluate genetic changes at the time of clinically overt t-MDS/
AML, we compared gene expression in BM cells at t-MDS/AML
from cases with BM samples obtained from controls at compa-
rable time points post-aHCT (Figure 2A). We did not observe
significant differences in distribution of subsets of CD34+ cells
(HSC, CMP, GMP, and MEP) in a subset of t-MDS/AML cases
(n = 5) and controls (n = 6) (Figure S2A), indicating that the
gene expression differences identified in CD34+ cells were not
simply a reflection of differences in cellular composition and
were related to t-MDS/AML. GSEA analysis (Table 2; Table S5)
showed significantly downregulated gene sets related to cell
cycle regulation, DNA replication (Figure S2B), DNA repair (Fig-
ure S2B), hematopoietic differentiation, mitochondria, protea-
some, citrate cycle, and amino acid metabolism in t-MDS/AML
cases. Genes related to G protein coupled receptors, cellCancommunication (Figure S2B), and hematopoietic regulatory
factors were upregulated in cases. There was increased expres-
sion of genes with bindingmotifs for hematopoietic regulatory TF
including GFI1, GATA1, and OCT1, and reduced expression of
genes with binding motifs for E2F1 in cases (Table S5). IPA
and GO analysis confirmed significantly downregulated DNA
damage response, DNA repair and cell cycle regulation, and up-
regulated cell communication and adhesion in cases compared
with controls (Table S5). Of note, several gene sets enriched in
BM CD34+ cells at time of t-MDS/AML were also enriched in
PBSC CD34+ cells obtained pre-aHCT, long before the onset
of clinical disease. This is illustrated in Figure 2B where gene
sets significantly upregulated (n = 10) or downregulated (n =
185) in both PBSC and t-MDS/AML samples are highlighted.
A 50-gene t-MDS/AML signature derived from differential gene
expression at time of t-MDS/AML was significantly enriched in
PBSC from cases (downregulated) (normalized enrichment
scores = 1.84, p value < 0.001, false discovery rate [FDR] =
1.0%).
Expression of enriched genes from representative gene sets in
individual subjects is shown in Figure 2C. At time of t-MDS/AML,
BM from five cases showed gene expression resembling that of
controls. Four of these cases presented with transient del (20q)
or del (13q) abnormalities, three of whom had also shown gene
expression resembling that of controls in the corresponding
PBSC samples. The fifth patient presented with AML with del
(7q). The remaining seven cases with clearly altered gene sets
compared to controls presented with overt t-MDS/AML.
We also compared gene expression CD34+ cells from t-MDS/
AML patients with normal BM CD34+ cells. A heat map showing
up- and downregulated genes in t-MDS/AML compared with
normal CD34+ cells (FC > 2 and FDR < 0.05, 133 genes) is shown
in Figure S2C. We observed difference in gene sets enriched in
this analysis with those enriched when comparing t-MDS/AML
samples with samples from control NHL/HL patients who did
not develop t-MDS/AML (Table S6). We also compared gene
expression in normal BM CD34+ cells with control NHL/HL
patients who did not develop t-MDS/AML (Figure S2D and Table
S6). There was considerable overlap in gene sets enriched in BM
CD34+ cells from t-MDS/AML and control NHL/HL patients
compared to normal CD34+ cells with 87 of 219 significant
gene sets (40%) common to both analysis, as shown in Fig-
ure S2E. These results suggest a significant contribution of
underlying disease, therapeutic exposures and hematopoietic
regeneration post-aHCT to gene expression changes observed
in t-MDS/AML CD34+ cells, and support the experimentalcer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 595
Figure 2. Altered Gene Expression in BM CD34+ Cells at Time of t-MDS/AML Compared with Controls
(A) Differences in gene expression between cases and controls at time of t-MDS/AML are shown for top 50 genes with smallest p values and 4-fold change in OR
(OR > 4 or OR < 0.25).
(B) Normalized enrichment scores (NES) from GSEA analyses for altered gene sets in PBSC CD34+ and BMCD34+ cells at time of t-MDS/AML are plotted. Gene
sets significantly upregulated (n = 15) or downregulated (n = 203) in both PBSC and t-MDS/AML samples with FDR < 5% are highlighted and representative gene
sets listed in the boxes. A 50-gene t-MDS/AML signature set representing gene differentially expressed at time of development of t-MDS/AML is also shown.
(C) Expression of representative gene sets in BM CD34+ cells from individual cases at time of t-MDS/AML and controls is shown. The expression was averaged
over the genes in each gene set and hierarchical clustering performed for samples within the case and control groups. The box indicates the five cases with gene
expression resembling that of controls. See also Figure S2 and Table S6.
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Table 2. Gene sets enriched in BM CD34+ cells from patients at
time of development of t-MDS/AML
NES
FDR q
Value
Enriched in cases
G-Protein coupled receptors
HSA04080_NEUROACTIVE_LIGAND_
RECEPTOR_INTERACTION
3.11 <0.001
GPCRDB_CLASS_A_RHODOPSIN_LIKE 2.70 <0.001
GPCRS_CLASS_A_RHODOPSIN_LIKE 2.69 <0.001
MONOAMINE_GPCRS 2.50 <0.001
PEPTIDE_GPCRS 1.80 0.143
Cell adhesion/communication
HSA01430_CELL_COMMUNICATION 2.59 <0.001
HSA04512_ECM_RECEPTOR_INTERACTION 2.22 0.001
HSA04514_CELL_ADHESION_MOLECULES 1.94 0.016
Hematopoietic regulation
HSA04340_HEDGEHOG_SIGNALING_PATHWAY 2.04 0.012
Enriched in controls (reduced in cases)
Cell cycle regulation/checkpoints
SERUM_FIBROBLAST_CELLCYCLE 3.34 <0.001
DNA_REPLICATION_REACTOME 3.15 <0.001
P21_P53_ANY_DN 3.12 <0.001
P21_P53_MIDDLE_DN 2.87 <0.001
CELL_CYCLE 2.77 <0.001
CELL_CYCLE_KEGG 2.70 <0.001
HSA04110_CELL_CYCLE 2.63 <0.001
DNA_DAMAGE_SIGNALING 2.45 <0.001
GOLDRATH_CELLCYCLE 2.42 0.002
Hematopoietic stem cells
HSC_LATEPROGENITORS_ADULT 2.60 <0.001
HSC_LATEPROGENITORS_SHARED 2.58 <0.001
HSC_LATEPROGENITORS_FETAL 2.57 <0.001
HSC_INTERMEDIATEPROGENITORS_ADULT 2.51 <0.001
HSC_EARLYPROGENITORS_SHARED 2.47 <0.001
HSC_INTERMEDIATEPROGENITORS_SHARED 2.39 <0.001
Metabolism
PENG_LEUCINE_DN 2.56 <0.001
KREBS_TCA_CYCLE 2.55 <0.001
PENG_GLUTAMINE_DN 2.43 <0.001
HSA00020_CITRATE_CYCLE 2.26 <0.001
Mitochondria and oxidative phosphorylation
MITOCHONDRIA 2.66 <0.001
HUMAN_MITODB_6_2002 2.58 <0.001
ELECTRON_TRANSPORT_CHAIN 2.42 <0.001
Proteasome pathway
PROTEASOMEPATHWAY 2.30 <0.001
PROTEASOME 2.16 <0.001
DNA repair
BRENTANI_REPAIR 2.91 <0.001
FDR, false discovery rate; NES, normalized enrichment scores. See also
Table S5.
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Candesign of using controls with similar disease and therapeutic
exposure as t-MDS/AML cases to identify changes in gene
expression specific to t-MDS/AML. On the other hand compar-
ison with normal BM helps place changes in CD34+ cells from
t-MDS/AML patients in the context of changes in controls that
do not develop t-MDS/AML post-aHCT. For example expression
of cell cycle and oxidative phosphorylation-related genes is
increased in HL/NHL controls compared to normal CD34+ cells,
suggesting that the reduction in these pathways in t-MDS/AML
samples compared to controls may reflect a failure to upregulate
these pathways post-aHCT.
Changes in Gene Expression from Pre-aHCT
to Development of t-MDS/AML
To assess the evolution of genetic changes from pre-aHCT to
development of clinically overt disease, we compared changes
in individual gene expression in cases from PBSC collection
pre-aHCT to time of t-MDS/AML post-aHCT, with controls
over a similar time period (D t-MDS/AML-PBSC). GSEA analysis
of genes showing increased or decreased expression over time
was performed (Table S7). Significant gene sets (FDR < 5%) are
illustrated in Figure 3A. Gene sets downregulated at time of
t-MDS/AML but not in PBSC reflect changes acquired during
development of t-MDS/AML. Genes related to early lymphoid
progenitors were present in this group. In addition several
gene sets downregulated in both pre-aHCT and t-MDS/AML
samples showed significantly enhanced downregulation at
time of t-MDS/AML compared to pre-aHCT samples, indicating
progression of these alterations during t-MDS/AML develop-
ment. These included genes related to cell cycle regulation,
DNA repair, genotoxic stress response, and hematopoietic
maturation. Other gene sets were downregulated in PBSC but
not at t-MDS/AML, or showed enhanced downregulation in
PBSC compared to t-MDS/AML, likely representing alterations
important early in the course of t-MDS/AML development. These
included genes related to antioxidant response, mitochondrial
oxidative phosphorylation, and ribosomes.
Gene expression changes at different stages of development
of t-MDS/AML are summarized in Figure 3B. PBSC from patients
who develop t-MDS/AML demonstrate downregulation of mito-
chondrial, oxidative phosphorylation, protein synthesis, cell
cycle checkpoint, and DNA repair, and upregulation of GPCR,
cell adhesion, and certain hematopoietic transcription factors.
These gene alterations continue to be present at the time of
development of t-MDS/AML. However progression to t-MDS/
AML is associated with further downregulation of cell cycle
checkpoint, DNA repair, genotoxic response, and hematopoietic
differentiation genes.
Outcome Prediction
Because gene expression in PBSC samples from the training set
was associatedwith later development of t-MDS/AMLwe sought
to identify a PBSC gene signature that could identify NHL and
HL patients pre-aHCT at high risk for developing t-MDS/AML
following aHCT. PBSC samples from the training set were used
to derive the gene signature that was then applied to an indepen-
dent test set of 16 patients who subsequently developed
t-MDS/AML after aHCT for NHL or HL, and 20 matched controls
that did not develop t-MDS/AML (Figure 4A; Table S2). Thecer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 597
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Figure 3. Changes in Gene Expression in CD34+ Cells in the Course of Development of t-MDS/AML
(A) Changes in gene expression from PBSC to development of t-MDS/AML. Normalized enrichment scores (NES) from GSEA analyses for altered gene sets in
PBSC CD34+ and BM CD34+ cells at time of t-MDS/AML are plotted. Gene sets significantly upregulated (red) or downregulated (blue) in cases compared to
controls from time of PBSC collection to time of t-MDS/AML with FDR < 5% are highlighted and representative gene sets are listed in the boxes.
(B) Gene expression signatures that are upregulated and downregulated in cases compared to controls in PBSC and at time of development of t-MDS/AML, as
well as changes in gene expression from time of PBSC to development of t-MDS/AML are summarized. See also Table S7.
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Genetic Alterations Preceding Leukemia Developmentlength of follow up for cases was 44 months (range, 4.9–
101 months) and for controls was 76 months (range, 34–
138 months). The clinical and demographic characteristics of
t-MDS/AML patients in the training and test sets revealed differ-
ences in primary diagnosis, time to t-MDS/AML, and cytogenetic598 Cancer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Incabnormalities (Table S8). However, patients in the two sets did
not differ by age at diagnosis or HCT, number of stem cell collec-
tions, stem cell dose infused, stem cell mobilization techniques,
conditioning regimens, and pre-aHCT exposure to radiation or
topoisomerase II inhibitors. Independent analysis of differential.
Figure 4. Validation of Altered Gene Expression in PBSC from t-MDS/AML Cases and Outcome Prediction
(A) Strategy for development and validation of a gene signature to differentiate PBSC from cases and controls. PAM represents prediction analysis ofmicroarrays.
(B) Normalized enrichment scores (NES) fromGSEA analyses for 665 gene sets with FDR < 5% in PBSC CD34+ from either training set or test set are highlighted.
A total of 636 (95.6%) sets were in agreement between the two studies, with 34 gene sets upregulated and 602 gene sets downregulated in both training and
test sets.
(C) Expression for the 38-gene signature derived using PAM in the training PBSC set.
(D) Expression for the 38-gene signature in the test PBSC set. The boxes indicate the three subjects that were misclassified by the gene signature. See also
Figure S3, Table S8, Table S9, Table S10, and Table S11.
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Genetic Alterations Preceding Leukemia Developmentgene expression between cases and controls in the test set
revealed extensive overlap of up and downregulated gene sets
in t-MDS/AML cases between training and test sets (Figure 4B;
Table S9). Gene expression changes related to mitochondria,
metabolism, cell cycle regulation, and hematopoietic progeni-
tors that were observed in the training set were validated in
the test set (Table 1). A cross-validated 38-gene classifier was
derived from the training set using prediction analysis of microar-
ray (PAM) (Table S10). Expression of the 38-gene signature inCanboth training and test sets is shown in Figures 4C and 4D. Hier-
archical clustering of the 38 genes revealed two major clusters
with significant correlation for up- and downregulated expres-
sion of genes in cases or controls in training and test sets (p <
0.001). Application of the 38-gene signature to the test set
correctly classified 19 of the 20 subjects who did not subse-
quently develop t-MDS/AML, and 14 of the 16 subjects who
did develop t-MDS/AML (Figure S3A). There was significant
correlation between predicted and true disease status (19/20cer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 599
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Genetic Alterations Preceding Leukemia Developmentcontrols [95%] and 14/16 cases [87.5%], p < 0.001). The 38-gene
classifier had an accuracy of 33/36 = 91.7% and a precision
(positive predictive value) of 14/15 = 93.3%. The specificity of
the test was 19/20 = 95% and the sensitivity was 14/16 =
87.5%. It is noteworthy that gene expression signatures derived
from the training set were predictive of case versus control status
in the test set despite differences in clinical characteristics
between the two sets, suggesting that the gene expression
signature is robust across different subsets of t-MDS/AML. The
two t-MDS/AML patients who were misclassified presented
with features typical of t-MDS/AML and did not have any identifi-
able characteristics that distinguished them from other patients
in the set. The control patient whowasmisclassified did not differ
from other controls in terms of clinical features but developed
relapse of lymphoma 3 years after aHCT and underwent alloge-
neic transplantation, and could not be followed further for devel-
opment of t-MDS/AML. The misclassification of these samples
may reflect a degree of heterogeneity in gene expression of
CD34+ cells obtained from patients at time points prior to devel-
opment of t-MDS. Repetition of the analysis after removing the
two training cases with transient t-MDS/AML (#11 and #168)
and their respective controls yielded a 31-gene signature that
misclassified 4/16 cases in the test set as controls and 1/20
controls in the test set as cases (Figure S3B), and did not improve
the error rate compared with the original gene signature. These
results indicate that the gene expression profile of hematopoietic
cells pre-aHCT can reliably and accurately identify patients at
risk for t-MDS/AML post-aHCT.
It was previously reported that same cytogenetic abnormality
observed at the time of t-MDS diagnosis could be detected in
pre-aHCT specimens by FISH. (Abruzzese et al., 1999) Cytoge-
netic analysis performed on pre-aHCT bone marrow (BM)
samples for all subjects in this study did not show evidence of
clonal chromosomal abnormalities characteristic of t-MDS/
AML (Table S11). FISH analysis performed on a subset of
CD34+ cells from PBSC samples (n = 9), which were representa-
tive of the spectrum of cytogenetic abnormalities seen, and for
which sufficient samples were available, did not show evidence
of the t-MDS/AML clone in PBSC CD34+ cells (Table S11).
Therefore cells bearing clonal cytogenetic abnormalities do not
contribute significantly to the altered gene expression profile in
PBSC CD34+ cells from t-MDS cases. The difference between
our results and previous reports in the literature may reflect the
practice of routinely performing cytogenetic analyses on pre-
HCT BM samples from patients undergoing aHCT at our center.
Mitochondrial Dysfunction in PBSC from Patients Who
Later Developed t-MDS/AML
Gene signatures related to mitochondrial oxidative phosphoryla-
tion were prominently downregulated in PBSC CD34+ cells from
cases. The mitochondrial electron transport chain, in addition to
its role in energy production, is a major site of reactive oxygen
species (ROS) generation (Kowaltowski et al., 2009). Impaired
electron transfer could lead to increased ROS generation in
CD34+ cells from patients who develop t-MDS/AML (Wallace,
2005). We conducted additional studies of mitochondrial func-
tion in PBSC cells from cases and controls. PBSC CD34+ cells
from cases showed increased baseline levels of mitochondrial
ROS (p = 0.04) and total ROS (p = 0.07) compared to controls600 Cancer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc(Figure 5A). PBSC CD34+ cells from cases also demonstrated
reduced expression of antioxidant genes, which may further
increase ROS levels. Q-PCR analysis showed significant down-
regulation of the antioxidant genes hmox1 (p = 0.0016), prdx3
(p = 0.01), and sod2 (p = 0.001), in PBSC from cases compared
to controls (Osburn and Kensler, 2008) (Figure 5B). PBSC from
cases exhibited sustained elevation of ROS following exposure
to oxidative stressors including etoposide, nitrogen mustard
and methylene blue with visible light compared to controls,
consistent with reduced ROS detoxification (Figure 5C). We
observed significantly increased g-H2AX levels in PBSC from
cases after exposure to mechlorethamine (nitrogen mustard,
p = 0.0281), and a trend toward increased g-H2AX levels after
radiation and etoposide treatment (p = 0.065 and 0.083, respec-
tively), indicating increased DNA damage (Kinner et al., 2008)
(Figure 5D). PBSC from cases also demonstrated significantly
reduced NADH levels compared to controls, both with and
without treatment with the electron transport chain inhibitor
Rotenone, suggesting impaired NADH production (Grivennikova
and Vinogradov, 2006) (Figure 5E). This observation is consistent
with reduced TCA cycle activity and a broad defect in mitochon-
drial energymetabolism. Mitochondrial mass, estimated through
measurement of mitochondrial DNA content, was increased in
PBSC from cases compared to controls, possibly representing
a compensatory response to mitochondrial dysfunction or re-
duced autophagy of damaged mitochondria (Nugent et al.,
2007; Tolkovsky, 2009) (Figure 5F). We did not observe signifi-
cant differences in ROS levels both at baseline (n = 6) and
after exposure to oxidative stress (n = 5) in CD34+ subsets
(LT-HSC, CMP, GMP, MEP) selected by flow cytometry from
normal PBSC samples (Figure S4). Therefore differences in
ROS levels between PBSC CD34+ cells from t-MDS/AML cases
and controls cannot be explained by differences in their cellular
composition. These results indicate that PBSC CD34+ cells from
cases that develop t-MDS/AML have alteredmitochondrial func-
tion, increased ROS generation, reduced ROS detoxification,
and enhanced DNA damage after therapeutic exposure, and
support the results of gene expression analysis.
DISCUSSION
Changes in gene expression associated with development of
t-MDS/AML after aHCT for lymphoma were identified in CD34+
cells from PBSC obtained pre-aHCT, several months to years
before development of clinically overt disease. These changes
may represent factors predisposing to risk of t-MDS/AML and/or
effects of pre-aHCT therapeutic exposures. We identified a
38-gene signature in PBSC that could distinguish patients who
developed t-MDS/AML post-aHCT from those who did not.
This gene signature was validated in an independent set of
PBSC samples, supporting the potential prognostic utility of
this approach to identify patients at high risk for developing
t-MDS/AML.
PBSC CD34+ cells from patients who develop t-MDS/AML
demonstrate altered expression of genes related to mitochon-
dria, oxidative phosphorylation, oxidative stress response, ribo-
somes, and DNA repair. In additional studies we directly show
that PBSC CD34+ cells from cases that develop t-MDS/AML
demonstrate altered mitochondrial function, increased ROS.
Figure 5. Mitochondrial Dysfunction and Metabolic Abnormalities in PBSC from Patients Developing t-MDS/AML
(A) Mitochondrial ROS and total ROS levels in PBSC CD34+ cells from cases and controls detected with C-H2DCFDA and MitoSox RED respectively. Results
represent median, interquartile range, and range of values.
(B) Expression of Nrf2 regulated antioxidant genes heme oxygenase 1 (hmox1), peroxiredoxin 3 (prdx3), and superoxide dismutase 2 (sod2) in PBSC CD34+ cells
from cases (n = 20) and controls (n = 39) quantified using Q-PCR. Results represent median, interquartile range, and range of values.
(C) ROS levels in PBSCCD34+ cells from cases and controls, measured 2 hr after exposure to etoposide (VP-16), nitrogenmustard (NM), andmethylene bluewith
visible light (MB+Light) by C-H2DCFDA labeling. Results represent median, interquartile range, and range of values.
(D) DNA damage in PBSC CD34+ cells from cases and controls, measured 4 hr after exposure to radiation (2Gy), VP-16, and NM as well as no treatment controls
(NT) by measuring g-H2AX levels. Results represent median, interquartile range, and range of values.
(E) NADH levels in PBSC CD34+ cells from cases and controls measured at baseline and after rotenone treatment. Results represent median, interquartile range,
and range of values.
(F) Mitochondrial mass was estimated in PBSC MNC isolated from cases (n = 19) and controls (n = 16) through measurement of mitochondrial DNA content.
Results represent median, interquartile range, and range of values. See also Figure S4.
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Genetic Alterations Preceding Leukemia Developmentgeneration, reduced ROS detoxification, and enhanced DNA
damage after therapeutic exposure, validating and extending
the results of gene expression analysis. It is hypothesizedCanthat mitochondrial defects are central to cancer cell biology,
through enhanced ROS generation leading to mutation of critical
genes that regulate cell proliferation. Mitochondrial oxidativecer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 601
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Figure 6. ProposedModel for Pathogenesis
of t-MDS/AML
Therapeutic exposure to HSC results in elevated
ROS levels related to mitochondrial dysfunction.
Excessive ROS generation results in increased
DNA damage, cellular dysfunction and impaired
hematopoiesis. Impaired DNA repair and cell cycle
regulation leads to accumulation of mutations that
potentially contributes to the development of
t-MDS/AML.
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Genetic Alterations Preceding Leukemia Developmentphosphorylation, in addition to its role in energy production, is
a major source of ROS generation (Kowaltowski et al., 2009).
Impaired electron transfer could result in increased ROS gener-
ation in PBSC from patients at risk for t-MDS/AML (Wallace,
2005). Reduced antioxidant gene expression may further
increase ROS levels. Tight regulation of ROS is essential for
normal hematopoietic function (Ito et al., 2004). We have previ-
ously shown that development of t-MDS/AML post-aHCT is
preceded by impaired hematopoietic function evidenced by
impaired PBSC mobilization; reduced progenitor regeneration,
and accelerated telomere loss (Bhatia et al., 2005; Chakraborty
et al., 2009). Our findings support a model of t-MDS/AML where
therapeutic exposure results in increased ROS levels related to
mitochondrial dysfunction, increased DNA damage, mutagen-
esis, and impaired hematopoiesis (Figure 6). Impaired ribosomal
function may also contribute to hematopoietic impairment in
patients developing t-MDS/AML. Ribosomal gene mutations
and impaired ribosome biogenesis occur in congenital BM failure
syndromes and the 5q-syndrome, and may impair hematopoi-
esis through altered protein translation, or through p53-depen-
dent apoptosis and senescence (Ebert et al., 2008; Faber
et al., 2006; Fumagalli et al., 2009).
Changes in gene expression from PBSC to development of
t-MDS/AML likely represent additional abnormalities associated
with transformation from the pre-leukemic to leukemic state.
Progression to t-MDS/AML was associated with reduced ex-
pression of DNA repair and cell cycle regulatory genes, indi-
cating loss of genome protective mechanisms, potentially allow-
ing acquisition of additional mutations and disease evolution
(Harper and Elledge, 2007; Kastan and Bartek, 2004). Such
changes may result from acquisition of additional mutations or
epigenetic changes in pre-malignant cells. Mutations in HRR
genes are reported in t-MDS/AML patients (Rassool et al.,
2007). Increased expression of genes associated with cell cycle
progression was seen in a previous analysis of gene expression
in t-MDS/AML CD34+ cells (Qian et al., 2002), and mutations in
p53 are relatively frequent in t-MDS/AML (Ben-Yehuda et al.,
1996). Loss of p53-related cell cycle regulation may contribute
to genetic instability as well as survival and expansion of altered602 Cancer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc.hematopoietic cells in t-MDS/AML
(Feldser and Greider, 2007; Fumagalli
et al., 2009).
The observed heterogeneity in gene
expression with t-MDS/AML cases could
be related in part to alternative genetic
pathways to t-MDS/AML development,
as have been defined based on charac-teristic chromosome abnormalities (Pedersen-Bjergaard et al.,
2007). A previous analysis performed at time of development
of t-MDS/AML revealed that certain gene expression patterns
were common whereas others differed between different cyto-
genetic subgroups (Qian et al., 2002). Indeed in the current study
variability of gene expression was associated with certain types
of chromosomal abnormalities (20q-; 13q-). However, formal
analysis of difference in gene expression in samples among
different cytogenetic subgroups at early time points preceding
the development of t-MDS/AML requires assembly of an even
larger sample set.
The 38-gene predictor compares well with other recently re-
ported multigene signatures for various cancers. Although a per-
fect test should have 100% sensitivity and specificity, this is not
achieved by any currently available biomarker (Wagner et al.,
2004). For example, the best biomarker for prostate cancer,
PSA, has a sensitivity of 90% and specificity of 25%. A 29micro-
RNA-gene signature for nonsmall cell lung cancer in peripheral
blood mononuclear cells had 76% sensitivity and 82% speci-
ficity of prediction in an independent set of 38 cases and 17
controls (Raponi et al., 2009). A 75-probe signature in CD34+
cells predicted drug response to imatinib in CML patients with
88% sensitivity and 83% specificity in an independent test set
of 17 responders and 6 nonresponders (Oehler et al., 2009).
Thus, taking into account the previously published predictors,
the 38-gene signature for t-MDS/AML performed favorably
in classifying cases and controls. This is especially notable
because the signature was obtained from and applied to
samples procured several years prior to development of overt
disease. However, these findings are based on relatively small
numbers of patients and additional larger studies are required
as part of the stepwise development of this classifier to further
validate its predictive value prior to its application as a clinical
test. Furthermore, detection of this signature is currently limited
to PBSC obtained prior to aHCT, at a time when patients have
already been exposed to pre-aHCT therapeutic exposures. It
will be of interest to determine whether this signature can be
detected in samples obtained at diagnosis of NHL or HL, prior
to initiation of treatment.
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clinical significance, because early detection of patients at high
risk for t-MDS/AML using a gene expression signature could
facilitate application of interventions to prevent development of
this lethal malignancy. Detection of the high risk profile could
guide therapeutic decision-making including the use of alterna-
tive treatment approaches such as allogeneic transplantation
(Litzow et al., 2010), and application of targeted interventions
for those at high risk. Although interventions that reduce the
risk of progression to t-MDS/AML do not currently exist, insights
into critical molecular mechanisms contributing to susceptibility
to and emergence of t-MDS/AML could provide potential targets
for development of preventive or therapeutic interventional strat-
egies. For example, enhanced mitochondrial ROS levels can be
explored as a potential target for interventions to prevent t-MDS/
AML in patients receiving genotoxic cancer therapy (Colburn and
Kensler, 2008). These translational implications of our results
merit further investigation in future studies.
EXPERIMENTAL PROCEDURES
Patients and Samples
The study was approved by the institutional review board of City of Hope
(COH) in accordancewith an assurance filed with and approved by the Depart-
ment of Health and Human Services, and met all requirements of the Declara-
tion of Helsinki. Informed consent was obtained from all subjects. Patients
receiving aHCT for HL or NHL at COH constituted the sampling frame for
selection of cases and controls in this nested case-control study. PBSC
samples obtained pre-aHCT and BM samples at the time of development of
t-MDS/AML post-HCT were studied. The training set consisted of 18 patients
who developed t-MDS/AML (cases) after aHCT, matched with 37 controls
who underwent aHCT, but did not develop t-MDS/AML. Up to three controls
were selected per case, matched for primary diagnosis (HL/NHL), age at
aHCT (±10 years), and ethnicity (Caucasians, African-Americans, Hispanics,
other). Length of follow-up after aHCT for controls was longer than the time
from aHCT to t-MDS/AML in the corresponding case. The results of the
training set were validated in an independent group of 36 patients (test set)
consisting of 16 cases that developed t-MDS/AML post-aHCT for HL or
NHL, and 20 matched controls. Relevant demographic and clinical data
were obtained from medical records and included age at diagnosis and
aHCT, gender, race/ethnicity, disease characteristics, pre-aHCT cumulative
therapeutic exposures, conditioning regimens, priming with growth factors
and/or chemotherapy for PBSC mobilization and collection, number of
PBSC collections, dose of CD34+ cells infused, recovery of WBC counts, vital
status, and disease status after aHCT.
Gene Expression Analysis
In the training set, 55 PBSC samples from 18 cases and 37 matched controls
were studied. BM samples from time of development of t-MDS/AML were
available for 12 cases and 21 matched controls obtained at a comparable
time from aHCT. For validation, 36 PBSC samples from a test set consisting
of 16 cases and 20 matched controls were studied. All samples had been cry-
opreserved as mononuclear cells in liquid nitrogen. Frozen cells were thawed
and incubated in IMDM supplemented with 20% FBS and DNase I (Sigma)
for 3 hr incubation at 37C. Samples were labeled with anti-CD34-APC and
anti-CD45-FITC (BD Biosciences, San Jose, CA) and CD34+CD45dim cells
selected using flow cytometry (Beckman-Coulter, Miami, FL). Total RNA was
extracted using the RNeasy kit (QIAGEN). RNA from 1000 cells was amplified
and labeled using GeneChip Two-Cycle Target Labeling and Control Reagents
from Affymetrix (Santa Clara, CA). Fifteen micrograms of cRNA each was
hybridized to Affymetrix HG U133 plus 2.0 Arrays.
Statistical Analysis
Microarray data were analyzed using R (version 2.9) with genomic analysis
packages from Bioconductor (version 2.4). Details of analysis are providedCanin the supplemental experimental procedures. Following quality control, data
for PBSC and BM samples were normalized separately. Probesets with low
expression or variability were filtered. Using CLM to retain matching between
cases and controls, we analyzed the magnitude of association (expressed
as OR) between t-MDS/AML and (1), gene expression levels in PBSC at the
pre-aHCT time point; (2), gene expression levels in BM at time of t-MDS/
AML; and (3), change in expression of individual genes from PBSC to develop-
ment of t-MDS/AML. FDRwas applied to adjust for multiple testing. GSEAwas
performed on ranked lists of genes differentially expressed between cases and
controls generated using CLM. Where multiple significant gene sets were
related to each other, analysis was performed to identify a subset of common
enriched genes. Hierarchical clustering was performed within each of the case
and control group. GO and pathway analysis was performed using DAVID
2008 and Ingenuity IPA 7.5, respectively.
The association between gene expression in the PBSC product and subse-
quent development of t-MDS/AML identified in the training set was validated in
the test set. Differential expression between cases and controls was analyzed
using CLM. GSEA analysis was performed on the ranked list of differentially
expressed genes. PAM was used to derive a prognostic gene signature from
the training set to classify patients as case or control. Based on the misclassi-
fication error in cross-validation, a 38-gene signature was selected for predic-
tion and applied to the test set.
ROS Detection
To detect ROS, PBSCMNCs were incubated with carboxy-H2DCFDA (10 mM)
andMitoSOXRed (3 mM) (Invitrogen, Carlsbad, CA) at 37C for 30min to detect
total ROS and mitochondrial ROS respectively after exposing to etoposide
(VP-16, 34 nM), mechlorethamine (NM, 2 mg/ml), or methylene blue with visible
light. Cells were then labeled with anti-CD34-PE-Cy7, anti-CD45-APC-Cy7
(Ebioscience, San Diego, CA), and AnnexinV-Cy5 (BD Biosciences) on ice
for 30min, washed, and immediately analyzed by flow cytometry using a LSRII
flow cytometer (BD Biosciences).
Antioxidant Gene Expression
For antioxidant gene expression measurement, 10 ng total RNA from FACS-
sorted PBSC CD34+ cells was used to generate cDNA using SuperScript III
First-Strand Synthesis System (Invitrogen). Quantitative RT-PCR for expres-
sion of heme oxygenase 1 (hmox1), peroxiredoxin 3 (prdx3), and superoxide
dismutase 2 (sod2) was performed on an 7900HT Fast Real-Time PCR System
using TaqMan gene expression assays (Applied Biosystems, Foster City, CA).
Results were normalized to endogenous control b2-microglobulin (b2m)
expression.
DNA Damage Analysis
DNA damage was evaluated based on g-H2AX level using flow cytometry.
PBSC MNCs were treated with irradiation (2Gy), etoposide (VP-16, 34 nM)
or mechlorethamine (nitrogen mustard, 2 mg/ml) and g-H2AX levels were
detected in CD34+ fractions 4 hr after removal of DNA damage inducers by
staining with anti-phospho-Histone H2A.X (Tyr142) (Millipore, Temecula, CA)
following the protocol from the manufacturer.
NADH Detection
NADH levels in PBSC CD34+ cells were assessed by endogenous cellular
fluorescence measured at an excitation of 350 nm and an emission of
440nm using LSRII flow cytometer.Median fluorescence intensity was normal-
ized to control unlabeled beads (BD Biosciences) for each sample.
ACCESSION NUMBERS
Microarray data has been deposited in the Gene Expression Omnibus data-
base (accession number GSE23025).
SUPPLEMENTAL INFORMATION
Supplemental Information includes eleven tables, four figures, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2011.09.011.cer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 603
Cancer Cell
Genetic Alterations Preceding Leukemia DevelopmentACKNOWLEDGMENTS
This work was supported by NIH grants R01 HL083050 and P50 CA107399
and General Clinical Research Center Grant 5M01 RR00043.We thankMarilyn
Slovak for cytogenetic analysis, Paul Hengen and Xiwei Wu for assistance with
data analysis, and the City of Hope Analytical Cytometry, Cytogenetics, Func-
tional Genomics, and Bioinformatics shared resources. We are indebted to the
physicians and nurses of the Department of Hematology/HCT, and to all the
patients who participated in this study.
Received: September 22, 2010
Revised: July 2, 2011
Accepted: September 29, 2011
Published: November 14, 2011
REFERENCES
Abruzzese, E., Radford, J.E., Miller, J.S., Vredenburgh, J.J., Rao, P.N.,
Pettenati, M.J., Cruz, J.M., Perry, J.J., Amadori, S., and Hurd, D.D. (1999).
Detection of abnormal pretransplant clones in progenitor cells of patients
who developed myelodysplasia after autologous transplantation. Blood 94,
1814–1819.
Ben-Yehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A., Abeliovich,
D., Zelig, O., Yahalom, V., Paltiel, O., Or, R., et al. (1996). Microsatellite insta-
bility and p53 mutations in therapy-related leukemia suggest mutator pheno-
type. Blood 88, 4296–4303.
Bhatia, R., Van Heijzen, K., Palmer, A., Komiya, A., Slovak, M.L., Chang, K.L.,
Fung, H., Krishnan, A., Molina, A., Nademanee, A., et al. (2005). Longitudinal
assessment of hematopoietic abnormalities after autologous hematopoietic
cell transplantation for lymphoma. J. Clin. Oncol. 23, 6699–6711.
Bhatia, S., Ramsay, N.K., Steinbuch, M., Dusenbery, K.E., Shapiro, R.S.,
Weisdorf, D.J., Robison, L.L., Miller, J.S., and Neglia, J.P. (1996). Malignant
neoplasms following bone marrow transplantation. Blood 87, 3633–3639.
Chakraborty, S., Sun, C.L., Francisco, L., Sabado, M., Li, L., Chang, K.L.,
Forman, S., Bhatia, S., and Bhatia, R. (2009). Accelerated telomere shortening
precedes development of therapy-related myelodysplasia or acute myeloge-
nous leukemia after autologous transplantation for lymphoma. J. Clin. Oncol.
27, 791–798.
Chen, H.Z., Tsai, S.Y., and Leone, G. (2009). Emerging roles of E2Fs in cancer:
an exit from cell cycle control. Nat. Rev. Cancer 9, 785–797.
Colburn, N.H., and Kensler, T.W. (2008). Targeting transcription factors for
cancer prevention—the case of Nrf2. Cancer Prev. Res. (Phila.) 1, 153–155.
Ebert, B.L., Pretz, J., Bosco, J., Chang, C.Y., Tamayo, P., Galili, N., Raza, A.,
Root, D.E., Attar, E., Ellis, S.R., and Golub, T.R. (2008). Identification of RPS14
as a 5q- syndrome gene by RNA interference screen. Nature 451, 335–339.
Faber, P., Fisch, P., Waterhouse, M., Schmitt-Gra¨ff, A., Bertz, H., Finke, J., and
Spyridonidis, A. (2006). Frequent genomic alterations in epithelium measured
by microsatellite instability following allogeneic hematopoietic cell transplan-
tation in humans. Blood 107, 3389–3396.
Feldser, D.M., and Greider, C.W. (2007). Short telomeres limit tumor progres-
sion in vivo by inducing senescence. Cancer Cell 11, 461–469.
Fumagalli, S., Di Cara, A., Neb-Gulati, A., Natt, F., Schwemberger, S., Hall, J.,
Babcock, G.F., Bernardi, R., Pandolfi, P.P., and Thomas, G. (2009). Absence of
nucleolar disruption after impairment of 40S ribosome biogenesis reveals an
rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 11,
501–508.
Grivennikova, V.G., and Vinogradov, A.D. (2006). Generation of superoxide by
the mitochondrial Complex I. Biochim. Biophys. Acta 1757, 553–561.
Gupta, R., Soupir, C.P., Johari, V., and Hasserjian, R.P. (2007).
Myelodysplastic syndrome with isolated deletion of chromosome 20q: an
indolent disease with minimal morphological dysplasia and frequent thrombo-
cytopenic presentation. Br. J. Haematol. 139, 265–268.
Han, J.Y., and Theil, K.S. (2007). Karyotypic identification of abnormal clones
preceding morphological changes or occurring with no definite morphological604 Cancer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Incfeatures of myelodysplastic syndrome: a preliminary study. Lab. Hematol. 13,
17–21.
Harper, J.W., and Elledge, S.J. (2007). The DNA damage response: ten years
after. Mol. Cell 28, 739–745.
Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama,
K., Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004). Regulation of
oxidative stress by ATM is required for self-renewal of haematopoietic stem
cells. Nature 431, 997–1002.
Kalaycio, M., Rybicki, L., Pohlman, B., Sobecks, R., Andresen, S.,
Kuczkowski, E., and Bolwell, B. (2006). Risk factors before autologous stem-
cell transplantation for lymphoma predict for secondary myelodysplasia and
acute myelogenous leukemia. J. Clin. Oncol. 24, 3604–3610.
Kang, J., Shakya, A., and Tantin, D. (2009). Stem cells, stress, metabolism and
cancer: a drama in two Octs. Trends Biochem. Sci. 34, 491–499.
Kastan, M.B., and Bartek, J. (2004). Cell-cycle checkpoints and cancer. Nature
432, 316–323.
Kinner, A., Wu, W., Staudt, C., and Iliakis, G. (2008). Gamma-H2AX in recog-
nition and signaling of DNA double-strand breaks in the context of chromatin.
Nucleic Acids Res. 36, 5678–5694.
Kowaltowski, A.J., de Souza-Pinto, N.C., Castilho, R.F., and Vercesi, A.E.
(2009). Mitochondria and reactive oxygen species. Free Radic. Biol. Med.
47, 333–343.
Krishnan, A., Bhatia, S., Slovak, M.L., Arber, D.A., Niland, J.C., Nademanee,
A., Fung, H., Bhatia, R., Kashyap, A., Molina, A., et al. (2000). Predictors of
therapy-related leukemia and myelodysplasia following autologous transplan-
tation for lymphoma: an assessment of risk factors. Blood 95, 1588–1593.
Lenka, N., Vijayasarathy, C., Mullick, J., and Avadhani, N.G. (1998). Structural
organization and transcription regulation of nuclear genes encoding the
mammalian cytochrome c oxidase complex. Prog. Nucleic Acid Res. Mol.
Biol. 61, 309–344.
Litzow, M.R., Tarima, S., Pe´rez, W.S., Bolwell, B.J., Cairo, M.S., Camitta, B.M.,
Cutler, C.S., de Lima, M., Dipersio, J.F., Gale, R.P., et al. (2010). Allogeneic
transplantation for therapy-related myelodysplastic syndrome and acute
myeloid leukemia. Blood 115, 1850–1857.
Mason, P.J. (2003). Stem cells, telomerase and dyskeratosis congenita.
Bioessays 25, 126–133.
Miller, J.S., Arthur, D.C., Litz, C.E., Neglia, J.P., Miller, W.J., andWeisdorf, D.J.
(1994). Myelodysplastic syndrome after autologous bone marrow transplanta-
tion: an additional late complication of curative cancer therapy. Blood 83,
3780–3786.
Nugent, S.M., Mothersill, C.E., Seymour, C., McClean, B., Lyng, F.M., and
Murphy, J.E. (2007). Increased mitochondrial mass in cells with functionally
compromised mitochondria after exposure to both direct gamma radiation
and bystander factors. Radiat. Res. 168, 134–142.
Oehler, V.G., Yeung, K.Y., Choi, Y.E., Bumgarner, R.E., Raftery, A.E., and
Radich, J.P. (2009). The derivation of diagnostic markers of chronic myeloid
leukemia progression from microarray data. Blood 114, 3292–3298.
Osburn, W.O., and Kensler, T.W. (2008). Nrf2 signaling: an adaptive response
pathway for protection against environmental toxic insults. Mutat. Res. 659,
31–39.
Pedersen-Bjergaard, J. (2005). Insights into leukemogenesis from therapy-
related leukemia. N. Engl. J. Med. 352, 1591–1594.
Pedersen-Bjergaard, J., Andersen, M.K., and Christiansen, D.H. (2000).
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose
chemotherapy and autologous stem cell transplantation. Blood 95, 3273–
3279.
Pedersen-Bjergaard, J., Andersen, M.T., and Andersen, M.K. (2007). Genetic
pathways in the pathogenesis of therapy-related myelodysplasia and acute
myeloid leukemia. Hematology (Am. Soc. Hematol. Educ. Program), 392–397.
Qian, Z., Fernald, A.A., Godley, L.A., Larson, R.A., and Le Beau, M.M. (2002).
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals
distinct subtypes of therapy-related acute myeloid leukemia. Proc. Natl.
Acad. Sci. USA 99, 14925–14930..
Cancer Cell
Genetic Alterations Preceding Leukemia DevelopmentRaponi, M., Dossey, L., Jatkoe, T., Wu, X., Chen, G., Fan, H., and Beer, D.G.
(2009). MicroRNA classifiers for predicting prognosis of squamous cell lung
cancer. Cancer Res. 69, 5776–5783.
Rassool, F.V., Gaymes, T.J., Omidvar, N., Brady, N., Beurlet, S., Pla, M.,
Reboul, M., Lea, N., Chomienne, C., Thomas, N.S., et al. (2007). Reactive
oxygen species, DNA damage, and error-prone repair: a model for genomic
instability with progression in myeloid leukemia? Cancer Res. 67, 8762–8771.
Stone, R.M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinowe,
S.N., Aster, J.C., Leavitt, P., Mauch, P., Freedman, A.S., et al. (1994).
Myelodysplastic syndrome as a late complication following autologous bone
marrow transplantation for non-Hodgkin’s lymphoma. J. Clin. Oncol. 12,
2535–2542.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., andCanMesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Tolkovsky, A.M. (2009). Mitophagy. Biochim. Biophys. Acta 1793, 1508–1515.
Tothova, Z., Kollipara, R., Huntly, B.J., Lee, B.H., Castrillon, D.H., Cullen, D.E.,
McDowell, E.P., Lazo-Kallanian, S., Williams, I.R., Sears, C., et al. (2007).
FoxOs are critical mediators of hematopoietic stem cell resistance to physio-
logic oxidative stress. Cell 128, 325–339.
Wagner, P.D., Verma, M., and Srivastava, S. (2004). Challenges for biomarkers
in cancer detection. Ann. N Y Acad. Sci. 1022, 9–16.
Wallace, D.C. (2005). Mitochondria and cancer: Warburg addressed. Cold
Spring Harb. Symp. Quant. Biol. 70, 363–374.cer Cell 20, 591–605, November 15, 2011 ª2011 Elsevier Inc. 605
